Angrimani Daniel S R, Bicudo Luana C, Llamas Luceño Nuria, Rui Bruno R, Silva Matheus F, Losano João D A, Leemans Bart, Van Soom Ann, Vannucchi Camila I
Department of Animal Reproduction, School of Veterinary Medicine and Animal Science, University of São Paulo, Av. Prof. Orlando Marques de Paiva, 87, São Paulo, 05508-270 Brazil.
Department of Reproduction, Obstetrics and Herd Health, Faculty of Veterinary Medicine, Ghent University, 9820 Merelbeke, Belgium.
Basic Clin Androl. 2020 Jul 16;30:9. doi: 10.1186/s12610-020-00108-2. eCollection 2020.
Benign prostatic hyperplasia (BPH) is one of the most common reproductive disorders in both male dogs and men. Finasteride, a synthetic inhibitor of the enzyme 5α-reductase, is widely used as medical treatment. Although sperm can be affected by both BPH and finasteride treatment, the direct influence on DNA integrity remains unclear. Thus, the aim of this study was to verify the direct effect of BPH and/or finasteride treatment on DNA integrity of dog spermatozoa. A 2 × 2 factorial experiment was designed with 20 male dogs assigned to 4 experimental groups: BPH Group ( = 5), BPH-Finasteride Group ( = 5), Non-BPH Finasteride-Treated Group (n = 5) and Non-BPH Untreated Group (n = 5). Sperm evaluation was performed monthly for 60 days after the start of finasteride therapy or BPH diagnosis (D0, D30 and D60). Sperm DNA integrity was analyzed through fragmentation susceptibility (toluidine blue staining and Sperm Chromatic Structure Assay - SCSA), direct evaluation of DNA fragmentation (Sperm Chromatin Dispersion Assay - SCDA) and sperm protamination (chromomycin A3).
Sperm DNA integrity was not affected by finasteride treatment. However, BPH dogs had higher susceptibility to sperm DNA acid denaturation (SCSA) compared to dogs not presenting BPH, as well as lower percentage of sperm with DNA integrity (toluidine blue staining).
In conclusion, benign prostatic hyperplasia causes post-testicular sperm DNA damage, albeit finasteride treatment itself does not directly influence sperm DNA integrity.
良性前列腺增生（BPH）是雄性犬类和男性中最常见的生殖系统疾病之一。非那雄胺是一种5α-还原酶的合成抑制剂，被广泛用作药物治疗。尽管精子会受到BPH和非那雄胺治疗的影响，但对DNA完整性的直接影响仍不清楚。因此，本研究的目的是验证BPH和/或非那雄胺治疗对犬精子DNA完整性的直接影响。设计了一个2×2析因实验，将20只雄性犬分为4个实验组：BPH组（n = 5）、BPH-非那雄胺组（n = 5）、非BPH非那雄胺治疗组（n = 5）和非BPH未治疗组（n = 5）。在非那雄胺治疗开始或BPH诊断后60天内每月进行一次精子评估（D0、D30和D60）。通过片段敏感性（甲苯胺蓝染色和精子染色质结构分析-SCSA）、DNA片段的直接评估（精子染色质扩散分析-SCDA）和精子鱼精蛋白（放线菌素A3）分析精子DNA完整性。
非那雄胺治疗对精子DNA完整性没有影响。然而，与未患BPH的犬相比，患BPH的犬对精子DNA酸变性（SCSA）的敏感性更高，并且DNA完整性正常的精子百分比更低（甲苯胺蓝染色）。
总之，良性前列腺增生会导致睾丸后精子DNA损伤，尽管非那雄胺治疗本身不会直接影响精子DNA完整性。
